+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A multicenter study on the surfactant treatment in late-preterm or term infants with respiratory distress syndrome



A multicenter study on the surfactant treatment in late-preterm or term infants with respiratory distress syndrome



Zhonghua Er Ke Za Zhi 52(10): 724-728



To investigate the efficacy and safety of surfactant when it was used to treat late-preterm or term infants with respiratory distress syndrome (RDS). Infants who were born at ≥34 weeks' gestational age and diagnosed with respiratory distress syndrome, required mechanical ventilation, admitted to 8 tertiary NICUs at <72 hours of age were enrolled. Surfactant was given if the infant required FiO2≥0.4 to maintain PaO2≥50 mmHg(1 mmHg=0.133 kPa) or SpO2>90%. Before and after surfactant treatment, the results of blood gas, ventilator settings, and the incidence of complications were recorded and analyzed. Comparison between continuous variables was made by t-test or one way analysis of variance (ANOVA). Categorical data was analyzed by a 2-tailed Pearson χ2 test. Totally 96 infants were enrolled in this prospective study. The mean gestational age was (36.5±2.1) weeks. Of whom, 71.9% (n=69) were male, 59.4% (n=57) were late-preterm infants, 62.5% (n=60) were delivered by elective cesarean section. The first dose of surfactant was given at the median age of 13.3 hours with the dosage of (109±20) mg/kg. The second dose was given to 10.4% (n=10) infants. Half an hour post surfactant, PaO2/FiO2, OI, A-aDO2, PaO2/PAO2 improved significantly, and lasted for 6 hours. The mean length of hospital stay was (19±9) days, median medical cost was (39,000±36,000) yuan. Totally 73 cases (76.0%) were discharged after the treatment completed. Compared to small dosage, the improvement of PaO2/FiO2, OI, A-aDO2, PaO2/PAO2 was more significant at 6 hours after relatively large dose (≥100 mg/kg) of surfactant, and the length of mechanical ventilation was shorter. But the length of hospital stay, medical costs, and the incidence of complications was not significantly different between these two dosage groups. Surfactant significantly improved the oxygenation in late-preterm or term infants with respiratory distress syndrome.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057072180

Download citation: RISBibTeXText

PMID: 25537535


Related references

Effects of surfactant treatment in late preterm infants with respiratory distress syndrome. Journal of Maternal-Fetal and Neonatal Medicine 31(10): 1259-1266, 2018

Early treatment of respiratory distress syndrome with bovine surfactant in very preterm infants: a multicenter controlled clinical trial. Pediatric Pulmonology 14(1): 4-9, 1992

Early use of calf pulmonary surfactant in late preterm and full-term infants with respiratory distress syndrome: a randomized controlled trial. Zhongguo Dang Dai Er Ke Za Zhi 16(3): 285-289, 2014

Analysis of the cost-effectiveness of surfactant treatment (Curosurf®) in respiratory distress syndrome therapy in preterm infants: early treatment compared to late treatment. Italian Journal of Pediatrics 40: 40, 2014

Surfactant therapy in late preterm infants: respiratory distress syndrome and beyond. Turkish Journal of Pediatrics 54(3): 239-246, 2012

Surfactant therapy in respiratory failure other than respiratory distress syndrome in term and preterm infants. Pediatric Research 31(4 Part 2): 323A, 1992

Modified bovine surfactant versus a protein-free surfactant in the treatment of respiratory distress syndrome in preterm infants A pilot study. Journal of the National Medical Association 86(1): 46-52, 1994

Preterm and term infants with acute respiratory distress syndrome (ARDS): what is the role of surfactant substitution?. Zeitschrift für Geburtshilfe und Neonatologie 213(2): 33-41, 2009

Genetic Factors Contribute to Risk for Neonatal Respiratory Distress Syndrome among Moderately Preterm, Late Preterm, and Term Infants. Journal of Pediatrics 172: 69-74.E2, 2016

Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant. Journal Of Pediatrics. 122(3): 446-452, 1993

Microvascular permeability of the lung following surfactant treatment in preterm infants with Respiratory Distress Syndrome. Biology of the Neonate 69(3): 221, 1996

Surfactant Treatment Threshold during NCPAP for the Treatment of Preterm Infants with Respiratory Distress Syndrome. American Journal of Perinatology 33(10): 925-929, 2018

Rapid improvement of static compliance after surfactant treatment in preterm infants with respiratory distress syndrome. Pediatric Pulmonology 15(3): 157-162, 1993

The effects of surfactant and antenatal corticosteroid treatment on the pulmonary pathology of preterm infants with respiratory distress syndrome. Pathology, Research and Practice 205(1): 35-41, 2009

Early prophylactic versus late selective use of surfactant for respiratory distress syndrome in very preterm infants: a collaborative study of 53 multi-center trials in Korea. Journal of Korean Medical Science 29(8): 1126-1131, 2014